TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33050900
Drug: Tezepelumab 210
Normalized name: TEZEPELUMAB 210 mg in 1.9 mL SUBCUTANEOUS INJECTION, SOLUTION [TEZSPIRE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezepelumab 210 mg administered subcutaneously every 4 weeks for 28 weeks
Study: 35780702
Drug: Delivered daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delivered daily dinner tray for 6 months with assistance during meals
Study: 35232755
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis with alteplase (IVT) + endovascular treatment (EVT)
Study: 34314727
Drug: Agent drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agent drug coated balloon (DCB)
Study: 36411659
Drug: Food supplement
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food supplement based on S-adenosyl methionine (SAMe, 200 mg/day) and probiotics (Lactobacillus helveticus Rosell®‐52, Bifidobacterium longum Rosell®‐175, 3 × 10^9 CFU/day)
Study: 34488361
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (internal anal sphincterotomy)
Study: 32916609
Drug: Semaglutide 2.4
Normalized name: semaglutide 2.4 MG in 0.75 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide 2.4 mg subcutaneously once weekly
Study: 35266243
Drug: Subcutaneous immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunoglobulin (SCIG; IgPro20 [Hizentra]) 0.2 g/kg
Study: 35266243
Drug: Subcutaneous immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunoglobulin (SCIG; IgPro20 [Hizentra]) 0.4 g/kg
Study: 33483355
Drug: 8-week educational
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8-week educational programme on top of usual treatment
Study: 34581424
Drug: QFR-guided complete
Approvals — FDA: no, EMA: no, PMDA: no
Description: QFR-guided complete revascularization (QFR-G-CR)
Study: 33692183
Drug: Scheduled 6-hourly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled 6-hourly IV acetaminophen for 48 hours post-cardiac surgery
Study: 35881907
Drug: Colchicine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (1 mg before PCI and 0.5 mg daily after until discharge)
Study: 35803757
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg intravenously after induction of anaesthesia
Study: 35202353
Drug: Standard 6-month
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 6-month regimen for tuberculosis treatment
Study: 34579763
Drug: Hishi extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hishi extract (100 mg/day)
Study: 34219000
Drug: Atezolizumab 840
Normalized name: atezolizumab 840 MG in 14 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 840 mg with paclitaxel 90 mg/m2
Study: 34219000
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with paclitaxel 90 mg/m2
Study: 33787411
Drug: Late endovascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late endovascular treatment in patients with clinical‐ASPECTS mismatch (NIHSS ≥ 10 and ASPECTS ≥ 7, or NIHSS ≥ 20 and ASPECTS ≥ 5)
Study: 33787411
Drug: Late endovascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late endovascular treatment in patients without clinical‐ASPECTS mismatch
Study: 32336008
Drug: Vandetanib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib (100 mg once daily)
Study: 36175936
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate Ringer's solution (BRS)
Study: 36175936
Drug: Sodium lactate
Normalized name: Sodium Lactate
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium lactate Ringer's solution (control group)
Study: 33896751
Drug: Transarterial infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transarterial infusion chemotherapy plus microsphere embolization for gastroesophageal cancer and transarterial chemoembolization for hepatic metastasis
Study: 33896751
Drug: Transarterial infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transarterial infusion chemotherapy for gastroesophageal cancer and transarterial chemoembolization for hepatic metastasis
Study: 33896751
Drug: Transarterial infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transarterial infusion chemotherapy plus microsphere embolization
Study: 34639295
Drug: Chuna manual
Normalized name: China-Gel
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chuna manual therapy (CMT) plus usual Korean traditional medicine care for three weeks (6-11 sessions)
Study: 34639295
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care including acupuncture, cupping, herbal medicine, moxibustion, and traditional physiotherapy
Study: 34639295
Drug: Chuna manual
Normalized name: China-Gel
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chuna manual therapy (CMT) plus usual Korean traditional medicine care
Study: 33167779
Drug: Machine learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine learning (ML) using support vector machines (SVM) and convolutional neural networks (CNN) trained on ventricular monophasic action potentials (MAPs) to predict sustained ventricular tachycardia/ventricular fibrillation (VT/VF) and mortality.
Study: 33167779
Drug: Machine learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine learning (ML) using support vector machines (SVM) and convolutional neural networks (CNN) trained on ventricular monophasic action potentials (MAPs) to predict mortality.
Study: 36335918
Drug: Initial invasive
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial invasive strategy added to guideline-directed medical therapy
Study: 33409923
Drug: Zinc, Vitamin
Normalized name: Vita-Zinc, Vitamin B Complex with C and Zinc oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc, Vitamin A, and Magnesium supplementation (30 mg zinc gluconate capsule per day, 250 mg magnesium oxide tablet per day, 25,000 IU vitamin A capsule twice/week for 10 weeks)
Study: 33409923
Drug: Placebo (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (placebo capsules and tablets for 10 weeks)
Study: 34648009
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion (loading dose of 0.5 μg/kg over 15 minutes followed by a maintenance dose of 0.2 μg/kg per hour)
Study: 32511775
Drug: Probiotic L.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic L. reuteri lozenges
Study: 35268094
Drug: Medium-Chain Triglycerides
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-Chain Triglycerides (MCTs) - 2 g daily for two weeks
Study: 35536382
Drug: Celery seed
Normalized name: CELERY SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celery seed extract (1.34 g extract per day)
Study: 32365242
Drug: Clobetasol cream
Normalized name: clobetasol Topical Cream
DrugBank: Clobetasol (DB11750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobetasol cream
Study: 35110003
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) - single dose of aluminum gallium arsenide (GaAlAs) laser irradiation (808 nm; 350 milliwatts; 3.5 joule/point) with placebo medication.
Study: 35110003
Drug: Paracetamol–caffeine tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol–caffeine tablets (3 times daily for the first couple of days after separator insertion, and as needed for the rest of the week) with placebo LED light.
Study: 32476089
Drug: Simple Oral
Normalized name: Simple Oral Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple Oral Exercise (SOE)
Study: 34512931
Drug: Oxycodone hydrochloride
Normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone hydrochloride injection combined with dexmedetomidine
Study: 34512931
Drug: Oxycodone hydrochloride
Normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone hydrochloride injection
Study: 36206793
Drug: Antibiotic review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic review kit intervention
Study: 32351183
Drug: Cannabidiol (CBD)
Normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol (CBD) treatment with a high level of CBD to low level of THC ratio
Study: 32351183
Drug: No pharmacological
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pharmacological treatment
Study: 34118059
Drug: ≥1000 IU/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: ≥1000 IU/day vitamin D3 (pooled higher doses)
Study: 32316978
Drug: Autologous dendritic
Normalized name: COVID19 s-vax loaded autologous dendritic cell vaccine
DrugBank: COVID19 s-vax loaded autologous dendritic cell vaccine (DB15814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous dendritic cell vaccines (DCV)
Study: 32316978
Drug: Autologous tumor
Normalized name: DNP-Modified autologous tumor vaccine
DrugBank: DNP-Modified autologous tumor vaccine (DB17436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous tumor cell vaccines (TCV)
Study: 36321411
Drug: Active titration
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active titration
Study: 36321411
Drug: Usual titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual titration
Study: 35060398
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behavioural therapy (CBT) for postpartum depression delivered by public health nurses plus treatment as usual (TAU)
Study: 35701773
Drug: Cinnamaldehyde mucoadhesive
Normalized name: Cinnamaldehyde
DrugBank: Cinnamaldehyde (DB14184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamaldehyde mucoadhesive patches
Study: 35701773
Drug: Placebo mucoadhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo mucoadhesive patches
Study: 35896943
Drug: Viloxazine ER
Normalized name: viloxazine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viloxazine ER (200–600 mg/day)
Study: 32172522
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (one‐time oral dose of 120,000 IU)
Study: 32172522
Drug: Placebo (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (8 mg of saccharide)
Study: 33992280
Drug: IASTM +
Normalized name: MASK,SURGICAL RECTANGULAR ASTM LEVEL 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IASTM + conventional treatment
Study: 35975719
Drug: Autologous Blood
Normalized name: Banked autologous blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous Blood Injection (ABI)
Study: 32601710
Drug: Intermittent Theta
Normalized name: Coptis teeta root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent Theta Burst Stimulation (iTBS) - 20 bilateral treatments (1 session per day, 5 days per week over a 4-week period)
Study: 34496450
Drug: Garlic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic supplementation (800 mg/day)
Study: 34151413
Drug: Doravirine 100
Normalized name: doravirine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doravirine 100 mg QD for 5 days
Study: 34151413
Drug: Islatravir 2.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Islatravir 2.25 mg QD for 14 days
Study: 34151413
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of islatravir 2.25 mg and doravirine 100 mg QD for 5 days
Study: 33283731
Drug: Decitabine combined
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine combined with low-dose CEG regimen (DCEG)
Study: 33283731
Drug: Decitabine combined
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine combined with low-dose CAG regimen (DCAG)
Study: 33283731
Drug: Decitabine combined
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine combined with low-dose CEG regimen (DCEG) and Decitabine combined with low-dose CAG regimen (DCAG)
Study: 34261600
Drug: Ghamz therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ghamz therapy
Study: 33852758
Drug: Gelato APF
Normalized name: Gelato APF 1.81 % Dental Foam
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gelato APF Gel
Study: 33284677
Drug: 1000 IU/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 IU/d or higher doses of vitamin D3
Study: 33284677
Drug: Experience-with-best-dose group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experience-with-best-dose group (1000 IU/d)
Study: 32135126
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg followed by misoprostol 200 mcg buccally
Study: 32135126
Drug: Placebo followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo followed by misoprostol 200 mcg buccally
Study: 35763247
Drug: Upacicalcet (0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upacicalcet (0.025 to 0.8 mg single-dose)
Study: 35763247
Drug: Upacicalcet (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upacicalcet (0.05 to 0.2 mg multiple-dose)
Study: 35333783
Drug: Targeted albumin
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted albumin infusions
Study: 32307430
Drug: Cytoflavin (intravenously,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin (intravenously, drip 20.0 ml in 250.0 ml 5% glucose for 14 days)
Study: 36226798
Drug: Medication reminder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication reminder app
Study: 34346168
Drug: 70 mg
Normalized name: silybin 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg astegolimab every 4 weeks
Study: 34346168
Drug: 210 mg
Normalized name: aspirin 210 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 210 mg astegolimab every 4 weeks
Study: 34346168
Drug: 490 mg
Normalized name: thimerosal 490 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 490 mg astegolimab every 4 weeks
Study: 33736675
Drug: Eribulin mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin mesylate (0.82 mg/m2/week in group A to 0.65 mg/m2/week in group D)
Study: 33444970
Drug: Almond consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almond consumption (2 servings, 56 g/day)
Study: 36495483
Drug: Oral ulipristal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ulipristal acetate regimens
Study: 33568086
Drug: Cochlear implants
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear implants (CI) in children aged 4-6 years
Study: 33568086
Drug: Cochlear implants
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear implants (CI) in children aged 7-9 years
Study: 32541143
Drug: Temsirolimus (TEM)
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Temsirolimus (TEM) 25 mg i.v. once a week
Study: 32541143
Drug: Sunitinib (SUN)
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib (SUN) 50 mg p.o. daily for 4 weeks on and 2 weeks off
Study: 36375173
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg duloxetine
Study: 34082620
Drug: Anemia treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anemia treatment (iron, erythropoiesis-stimulating agents, and/or red blood cell transfusion)
Study: 34082620
Drug: No anemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anemia treatment
Study: 33103322
Drug: Novel treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel treatments
Study: 36920778
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered subcutaneously every 2 weeks)
Study: 33440077
Drug: Letermovir (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letermovir (oral and intravenous administration)
Study: 35362109
Drug: QFR-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: QFR-based treatment recommendations
Study: 35362109
Drug: FFR-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FFR-based treatment recommendations
Study: 33296982
Drug: Salbutamol 2
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol 2 mg twice a day
Study: 34302758
Drug: Itepekimab 300
Normalized name: Itepekimab
DrugBank: Itepekimab (DB16206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itepekimab 300 mg administered as two subcutaneous injections every 2 weeks for 24-52 weeks
Study: 35430997
Drug: Ibuprofen/Caffeine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen/Caffeine combination (400/100 mg)
Study: 33504513
Drug: Double-dose clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose clopidogrel (600 mg, day 1; 150 mg, days 2-7; then 75 mg/day)
Study: 33504513
Drug: Standard-dose clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose clopidogrel (300 mg, day 1; then 75 mg/day)
Study: 34302129
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g l-arginine and 1.2 g aged garlic extract (AGE) daily for 6 weeks
Study: 33496884
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet supplemented with Zn-Met 60 mg/kg (T3)
Study: 33496884
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet supplemented with Zn-Met 40 mg/kg (T2)
Study: 33496884
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet supplemented with Zn-Met 20 mg/kg (T1)
Study: 33496884
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet (control, 40 mg/kg)
Study: 32323557
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D treatment (150,000 IU daily for 3 days before surgery)
Study: 34590235
Drug: Office-based extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Office-based extended-release naltrexone
Study: 36453001
Drug: Narrative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative therapy group sessions (8 weekly 2-hour sessions)
Study: 35948454
Drug: Strength training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength training plus proprioceptive neuromuscular facilitation (PNF) therapy
Study: 34683948
Drug: GF:IF =
Approvals — FDA: no, EMA: no, PMDA: no
Description: GF:IF = 0.5 with cumulative dose of 1.5 mg salbutamol
Study: 34683948
Drug: GF:IF =
Approvals — FDA: no, EMA: no, PMDA: no
Description: GF:IF = 1.0 with cumulative dose of 1.5 mg salbutamol
Study: 34683948
Drug: GF =
Normalized name: Glatiramer Acetate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GF = 50 L/min with cumulative dose of 1.5 mg salbutamol
Study: 34683948
Drug: GF:IF =
Approvals — FDA: no, EMA: no, PMDA: no
Description: GF:IF = 0.5 with cumulative dose of 3.5 mg salbutamol
Study: 34683948
Drug: GF:IF =
Approvals — FDA: no, EMA: no, PMDA: no
Description: GF:IF = 1.0 with cumulative dose of 3.5 mg salbutamol
Study: 34683948
Drug: GF =
Normalized name: Glatiramer Acetate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GF = 50 L/min with cumulative dose of 3.5 mg salbutamol
Study: 35794674
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine at a rate of 1 mg/h for the first 6 hours postoperatively, with adjustments based on NRS pain evaluation
Study: 35794674
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen 1 g every 6 hours and ketorolac 30 mg every 8 hours for the first 3 postoperative days
Study: 33386290
Drug: Optimal local
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal local treatment for nodal oligorecurrent prostate cancer
Study: 35842821
Drug: Compound microporous
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound microporous polysaccharide hemostatic powder (CMPHP)
Study: 32229495
Drug: Contezolid (MRX-I)
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contezolid (MRX-I) therapeutic dose (800 mg)
Study: 32229495
Drug: Contezolid (MRX-I)
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contezolid (MRX-I) supratherapeutic dose (1,600 mg)
Study: 32507624
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (BJ) supplementation (140 mL nitrate-rich BJ concentrate)
Study: 36044708
Drug: Carbohydrate (CHO:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (CHO: 1 g/kg/h)
Study: 33705205
Drug: Adavosertib monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adavosertib monotherapy (300 mg orally once daily on days 1-5 and 8-12 of a 21-day cycle)
Study: 36469840
Drug: Adavosertib monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adavosertib monotherapy
Study: 32075958
Drug: Oral cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cannabis (6.9% THC, 50.6 mg)
Study: 32075958
Drug: Smoked cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoked cannabis (6.9% THC, 50.6 mg)
Study: 32075958
Drug: Vaporized cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaporized cannabis (6.9% THC, 50.6 mg)
Study: 34162404
Drug: Standard intensive
Normalized name: MACADAMIA OIL 2 g in 100 g / CERAMIDE NP 0.0006 g in 100 g / PANTHENOL 0.75 g in 100 g / CENTELLA ASIATICA WHOLE 0.003 g in 100 g TOPICAL CREAM [ATO STANDARD INTENSIVECREAM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intensive chemotherapy